Cergentis news


New Nature publication; MSKCC uses TLA to QC CRISPR-mediated genome editing

| |
1 min read

On March 3rd, a new paper from the Memorial Sloan Kettering Cancer Center was published in Nature, entitled: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection".

The Targeted Locus Amplification (TLA) technology was used to sequence and map the AAV integrations.

View paper

© 2012-2022 Cergentis B.V. All rights reserved.
For Research Use Only. Not for use in diagnostic procedures.